DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.

Author(s): Kornstein SG, Kocsis JH, Ahmed S, Thase M, Friedman ES, Dunlop BW, Yan B, Pedersen R, Ninan PT, Li T, Keller M

Affiliation(s): aVirginia Commonwealth University, Richmond, Virginia bWeill Cornell Medical College, New York cWyeth Research, Collegeville dUniversity of Pennsylvania, Philadelphia eUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania fEmory University School of Medicine, Atlanta, Georgia gBrown University, Providence, Rhode Island, USA.

Publication date & source: 2008-11, Int Clin Psychopharmacol., 23(6):357-363.

The objective of this study was to evaluate the long-term efficacy of venlafaxine extended release (ER) </=225 mg/day in patients with recurrent major depressive disorder (MDD). In this double-blind trial, outpatients with recurrent MDD (N=1096) were randomized to 10 weeks of acute-phase treatment with venlafaxine ER (75-300 mg/day) or fluoxetine (20-60 mg/day) followed by a 6-month continuation phase and two consecutive 12-month maintenance phases. At the start of each maintenance period, venlafaxine ER responders were randomized to double-blind venlafaxine ER or placebo. In this analysis, data from responders to acute and continuation treatment were analyzed during the combined maintenance phases while receiving venlafaxine ER </=225 mg/day. Failure to maintain response was defined as an increase in maintenance dose to 300 mg/day or recurrence. Differences were calculated using Kaplan-Meier methods and compared using log-rank tests. Continuation-phase responders (n=114) receiving venlafaxine ER </=225 mg/day comprised the analysis population (venlafaxine ER: n=55; placebo: n=59). The estimated probability for remaining well across 24 months of maintenance treatment was 67% for venlafaxine ER and 41% for placebo (P=0.007). Venlafaxine ER effectively maintained response at doses </=225 mg/day for up to 2.5 years in patients with recurrent MDD. The findings are consistent with those of the full data set.

Page last updated: 2008-11-03

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017